. Whether a given genotype has an earlier emergence of 3TC resistance remains unclear. We thus conducted this study to elucidate the association of HBV genotype with the emergence of 3TC-resistant strains in Taiwanese patients. Methods: Forty chronic hepatitis B patients who developed resistance after 3TC therapy were retrospectively enrolled. HBV genotype, serum alanine aminotransferase (ALT) and HBV DNA levels were determined at baseline. The presence of 3TC-resistant mutations was confirmed by direct sequencing whenever biochemical breakthrough developed. Results: The distribution of HBV genotype B and C in 40 patients receiving 3TC therapy were 60% and 40%, respectively. The mean interval to detect 3TC-resistant strain was 19.6 ±1.7 months. By using multivariate analysis, HBV genotype B and higher pre-treatment HBV DNA level were independently associated with earlier detection of 3TC-resistant strains. In addition, genotype B was significantly associated with development of 3TC resistance within the first 12 months of 3TC therapy compared with genotype C (odds ratio 8.27; P=0.004). Conclusions: Compared with HBV genotype C, genotype B appears to have an earlier biochemical resistance to 3TC than genotype C. Therefore, more frequent monitoring of viral load or genotypical resistance might be needed for patients with HBV genotype B infection receiving 3TC therapy, especially during the first year.
Hepatitis B virus (HBV) infection is a global health problem [1] , and clinical manifestations of HBV infection include acute/fulminant hepatitis or various forms of chronic infection. Chronic HBV infection leads to inactive carrier state, chronic hepatitis, cirrhosis or hepatocellular carcinoma (HCC) [2, 3] . In Taiwan, the REVEAL-HBV study confirmed that the incidence rates of cirrhosis and HCC in adult HBV carriers positively correlate with serum HBV DNA level at enrolment in a dose-response relationship [4] . In order to minimize the adverse outcomes, the primary goal of chronic hepatitis B treatment is therefore to permanently suppress HBV replication [5] .
Lamivudine (3TC), one of the seven approved agents for the treatment of chronic hepatitis B, is safe, inhibits HBV replication, and has been shown to reduce hepatic fibrosis progression, cirrhosis complications as well as HCC risk [6, 7] . Because of the low cost of 3TC, it is extensively used worldwide, especially in developing countries. However, prolonged 3TC therapy is associated with a high drug resistance rate. Analysis on pooled controlled trials showed that
Original article
Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C Ting-Hui Hsieh 1 Introduction 3TC-resistant (3TC-R) HBV strains were detected in 16-32% of adult patients after 52 weeks of 3TC therapy [8] [9] [10] [11] , with increasing incidence in the following years [8, 11] along with diminished treatment response and long-term outcomes. Thus, timely detection of 3TC-R strains has become a vital issue during prolonged 3TC therapy in clinical practice, which can be successfully rescued by the early addition of adefovir dipivoxil treatment [12] .
Currently, eight HBV genotypes (A-H) are identified on the basis of divergence in the entire genome sequence of over 8%; each genotype has its specific ethnic and geographical distribution. Clinical outcomes and therapeutic differences have been reported among different HBV genotypes [13] [14] [15] [16] [17] [18] . In the Asia-Pacific region where HBV genotypes B and C are prevalent, previous longitudinal studies have shown that genotype B patients have a shorter duration of immune clearance phase with lower viraemia level and an earlier, more frequent hepatitis B e antigen (HBeAg) seroconversion [19] , which confers a favourable clinical outcome [3, 20, 21] . For patients with 3TC treatment, therapeutic responses do not significantly differ between genotype B and C infection. Nevertheless, whether a given genotype has an earlier emergence of 3TC-R HBV strains remains largely unknown. Taking advantage of widespread HBV infection in Taiwan and popular use of 3TC for the treatment of chronic hepatitis B, we conducted a retrospective study to elucidate the association of HBV genotype with the emergence of 3TC-R strains in Taiwanese patients.
Methods

Patients
A total of 40 chronic hepatitis B patients who developed 3TC-R during 3TC monotherapy (100 mg daily) were retrospectively screened and consecutively enrolled from the gastroenterology clinics of the National Taiwan University Hospital from July 1997 to August 2002. All were positive for hepatitis B surface antigen for at least 6 months before enrolment and negative for antibodies against hepatitis C virus, hepatitis D virus and HIV infection. Among them, 11 received interferon-based therapy prior to enrolment and the rest of them were naive to nucleoside/nucleotide treatment. Serum HBV DNA level, genotype, tyrosine-methionine-aspartate-aspartate (YMDD) status, alanine aminotransferase (ALT) value and HBeAg were determined at baseline. Because HBV DNA testing was not reimbursed by the health insurance system, only serum ALT and HBeAg were monitored at least every 3 months. HBV DNA level was assayed only when clinically indicated.
The detection of 3TC-R HBV strains was performed whenever a biochemical breakthrough occurred. Biochemical breakthrough was defined as an increase in serum ALT level above upper limit of normal after achieving normalization during continued treatment [22] . The interval between start of therapy and detection of 3TC-R strain was recorded. The primary endpoint of this study was the detection of 3TC-R HBV. Early emergence of 3TC-R was defined as a detectable mutation strain within 12 months of treatment.
Laboratory assays
Biochemical tests, including aspartate aminotransferase and ALT, were measured by a serum chemistry automatic analyzer (Model 736, Hitachi, Tokyo, Japan) with commercial reagents (Biomerieux, Marcy L'Etoile, France). Assays for serological markers were performed as follows: hepatitis B surface antigen, HBeAg and antibody to HBeAg (anti-HBe) by commercial kits (Abbott Laboratories, North Chicago, IL, USA); anti-HCV by using a second generation assay (Abbott Laboratories); serum anti-HDV was tested by a commercially available assay (Anti-Delta, Abbott Laboratories); and anti-HIV was tested by an enzyme immunoassay (Abbott Laboratories, Wiesbaden, Germany).
Quantification of HBV DNA, HBV genotyping and detection of 3TC-R HBV
HBV viral load and genotype were determined by using the real-time, PCR-based, single-tube assay as previously described [23] . Briefly, the method contained two consecutive steps. The first step used real-time PCR for quantification of HBV DNA and the second step used melting curve analysis for HBV genotyping. The detection limit of HBV DNA level by this method was 100 copies/ml.
The most common mutation involves substitution of methionine in the YMDD motif of the HBV DNA polymerase for valine or isoleucine (rtM204V/I) [24] . The presence of 3TC resistance was determined by PCR and subsequent direct sequencing with an automatic ABI DNA sequencer (Model 377A, Applied Biosystems, Foster City, CA, USA). To avoid false positive PCR results, we strictly followed the precautions described by Kwok and Higuchi [25] .
Sequences of basal core promoter region of HBV
The basal core promoter (BCP) region was directly sequenced as previously described [26] . Briefly, the BCP region was first amplified by nested PCR assays. The PCR products were then directly sequenced with an automatic ABI DNA sequencer (Model 377A; Applied Biosystems, Foster City, CA, USA) to determine the nucleotide sequences, with emphasis on nucleotides 1762 and 1764. The assay could detect the presence of the minor group (>20% of the whole viral population).
Ethical considerations
The study conformed to the provisions of 1975 Declaration of Helsinki and was approved by the institutional review board of the National Taiwan University Hospital. Serum sample was obtained after receiving written informed consent from each patient.
Statistical analysis χ
2 tests and t-tests were used to analyse categorical and continuous variables, respectively. The risk factors associated with the development of 3TC resistance were analysed using multivariate logistic regression and linear regression. Statistical analyses were performed by using Microsoft Excel ® 2007 SP1 (Washington, USA) and Stata 10 ® (StataCorp LP, College Station, TX, USA). Subgroup multivariate analyses were performed on baseline HBV DNA level, baseline ALT and time to mutation of 3TC-R by using a Probit model; P<0.05 was considered statistically significant.
Results
Among the 40 enrolled patients who developed 3TC-R strains after 3TC monotherapy, there were 35 males and 5 females. The mean age was 37.5 years (range 16-67). The mean treatment duration was 21.3 months (range 6-54), and the mean interval between start of 3TC therapy and detection of 3TC-R strains was 19.6 months (range 7-48). Twenty-six patients were positive for HBeAg and 14 were positive for antiHBe at baseline. At the time of detectable mutation, 5 patients (19%) had HBeAg seroconversion and 2 (14%) had seroreversion, resulting in 23 HBeAg-positive patients at that time. No mutation in the YMDD motif of the viral polymerase gene was detected at baseline. On analysis of YMDD motif at the time of detectable mutation, 23 patients had YIDD mutation, 16 had YVDD mutation, and 1 had mixed YIDD and YVDD mutation. Table 1 shows the characteristics of 3TC-R patients with HBV genotypes. No significant difference was found between genotype B and C patients with 3TC resistance in terms of age, sex, pre-treatment serum HBV DNA level, BCP status, ALT level, HBeAg status and seroconversion or seroreversion status at the time of detectable 3TC resistance.
Using the two-tailed t-test, genotype B patients tended to have a shorter interval to develop 3TC resistance than genotype C patients (17.2 versus 23.3 months; P=0.06). The cumulative incidence of the emergence of 3TC resistance during the follow-up period by genotypes at study entry is shown in Figure 1 . By defining detection of 3TC resistance within first 12 months as early emergence of 3TC resistance, we found that genotype B is associated with early emergence of 3TC resistance compared with genotype C (P=0.002; were independently associated with earlier detection of 3TC-R HBV strains (Table 2 ). In terms of early emergence of 3TC resistance, genotype B is significantly associated with development of 3TC resistance within the first 12 months (P=0.004) compared with genotype C, with an odds ratio (OR) of 8.27. 3TC-R mutation patterns (that is, YIDD or YVDD) were not associated with HBV genotype, pre-treatment HBV DNA level, age or gender (data not shown).
Discussion
Currently, the roadmap concept of HBV treatment suggests that the adjustment of the HBV treatment strategy should depend on the viral load at 24 weeks of therapy, which has been proven to influence the later development of resistant strains [27] . However, it is still difficult to predict the patients that will maintain viral suppression during 3TC therapy before the commencement of antiviral therapy. So far, several baseline factors have been associated with emergence of YMDD variants. Gender [28, 29] , body mass index [28] , HBeAg positivity [30] [31] [32] [33] , ALT level [29, 32] , high HBV DNA level [28, 30, [32] [33] [34] [35] and treatment duration [29, 32] were positively correlated with the risk of YMDD variants. Among these factors, HBeAg positivity [33, 36] , HBV DNA level [33, 36, 37] , precore stop codon variant [38] , higher ALT level [37, 38] By subgroup analysis of mutation within 12 months or beyond 12 months of lamivudine therapy. ALT, alanine aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B virus e antigen. Genotype C 16  16  14  10  8  3  1  1  0  Total  40  40  25  19  12  6  3  2  0 Total (n=40)
Genotype B (n=24)
HBV, hepatitis B virus.
and persistent viraemia during treatment [38, 39] were independently predictive of early development of 3TC resistance. Besides, BCP mutation has been reported to associate with virological breakthrough in 3TC-treated patients [40] . In contrast, the association of HBV genotype with the emergence of 3TC-R strain is still controversial [36, 41] . Although HBV genotype has not been linked to 3TC resistance in studies from Australia [38] and Japan [41] , other studies showed the opposite results. Genotype A was found to have an earlier emergence of 3TC resistance than genotype D in Germany [18] and genotype C HBV had a more rapid selection of 3TC resistance in China [33] . To solve this important issue in Taiwan, where HBV genotypes B and C prevail, we enrolled 40 patients who underwent 3TC therapy and monitored 3TC resistance closely during the follow-up. In line with our previous data [15] , genotype B and C were found in 60% and 40% of our patients, respectively. We further demonstrated that genotype B HBV was significantly associated with the earlier emergence of 3TC-resistant strains than genotype C, especially within the first year of treatment, by presenting with earlier biochemical breakthrough. However, the mechanisms involved in this phenomenon need additional examinations.
The importance of subgenotypes of HBV genotype B (Bj/B1 and Ba/B2) and genotype C (Cs/C1 and Ce/C2) have been noted recently [42, 43] . According to our previous studies [43, 44] , HBV/B1 is a rare subgenotype in Taiwan -the prevalence rate might be <0.67% [44] . For subgenotypes of HBV genotype C, the prevalence rate of HBV/C1 is approximately 10% [45] . The number of patients with genotype C infection was only 16 in this study; the case number is too small to evaluate the impact of subgenotype on 3TC resistance.
In a previous European study encompassing mostly genotype A and D patients [18] , HBV rtM204I mutants were prevalent in genotype D patients, whereas rtM204V mutants were common in genotype A patients. However, in this study, although the frequency of HBV rtM204I mutant was higher in genotype B patients (67%) than genotype C patients, the difference was statistically not significant. These findings were consistent with a previous Asian report [36] .
Several limitations existed in our study. First, the retrospective study design with relatively small number of patients might reduce the strength of our conclusions. Second, the time to determine the 3TC resistance was prolonged because of the study design. Genotypical resistance analysis was only performed whenever a biochemical breakthrough occurred, which was usually preceded by a few months of virological breakthrough. In addition, 3TC-R strain was detected by direct sequencing, of which the sensitivity is >20% of total viral populations. The combination of these two measures might lead to the underestimation of genotypical resistance rate. Third, it is also known that YMDD mutation occurs when early viral suppression could not be obtained after 3TC administration. The HBV DNA level at 6th month of treatment is important to predict 3TC-R emergence [27] . Whether early viral response to 3TC differs between HBV genotype B and C awaits further studies. Fourth, our data only compared the timing of 3TC-R development between HBV genotype B and C, rather than the incidence rate of 3TC-R. It is generally believed that there is no difference of 3TC-R development rate between HBV genotype B and C [26, 46] . Thus, HBV genotype might only influence the timing rather than the rate of 3TC-R. Despite these possible shortcomings, our data definitely showed that early and frequent detection of mutant strain by direct sequencing in HBV genotype B patients might still be helpful for practicing gastroenterologists and hepatologists. Whether these findings hold true for other nucleoside or nucleotide analogues awaits further investigations.
In summary, our data show that mutation patterns of YMDD motif do not differ between Taiwanese HBV genotype B and C patients. However, HBV genotype B seems to have an earlier biochemical resistance to 3TC than genotype C. In addition, more frequent monitoring of viral load or genotypical resistance might be needed for patients with HBV genotype B infection receiving 3TC therapy, especially during the first year.
